Page 10 - Martin Shkreli Case Study
P. 10
development. PhRMA (the pharmaceutical industry’s main lobbying
group) member companies have made similar arguments on the need to
price new drugs high enough to ensure that they have enough to cover
their R&D investments.
Although the pill costs about $1 to produce, Shkreli said that this price
did not include other costs like marketing and distribution.
He further said "We're simply charging the right price that the markets
[and] prior owners missed" and that:
- "We needed to turn a profit on this drug,"
- "The companies before us were just giving it away almost."
- “At this price it’s a reasonable profit,”
- “Not excessive at all.”
